DOCSLIB.ORG

MAY 2020 CATALOG MEDICATION CATALOG [email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MAY 2020 CATALOG MEDICATION CATALOG Admin@Tailormadecompounding.Com MAY 2020 CATALOG MEDICATION CATALOG [email protected] tailormadecompounding.com 1 859 887 0013 MEDICATION CATALOG 1 Table of contents Our Story 4-5 Marketing Sheets 6-21 • Anti-Aging 7 • Growth Hormone 8-9 • Hormone Replacement Therapies 10-12 • Iontophoresis 13-15 • Sexual Dysfunction 16-18 • Weight Loss Pack 19 • Weight Loss 20-21 Medication Fact Sheets 22-54 • 3-Desoxy DHEA 24 • Amlexanox 25 • Apomorphine 26 • Bupropion/Naltrexone 27 • Danazol 28 • Dasatinib/Quercetin 29 • Dexamethasone Iontophoresis Patches 30 • Enclomiphene 31 • Ergoloid Mesylates 32 • Glycyrrhetinic Acid & Aminophylline 33 • KPV 34 • Ketamine 35 • Melanotan I 36 • Metformin + DHEA + Sermorelin 37 • NAD+ 38 2 • Nandrolone 39 • Oxytocin 40 • Pentosan Polysulfate 41 Pitolisant 42 • Phentermine/Topiramate 43 • PT-141 44 • Rapamycin 45 Scream Cream 46 • Sermorelin 47 • Sermorelin/ GLycine 48 • Stanozolol 49 • Thymosin Alpha-1 50 • Thymosin Beta-4 51 • Trimix 52 • Vitamin D 53 • Whitening Cream 54 IV Therapy 55-62 • IV Therapy Protocols 56-60 • Implementing IV Therapy in Your Practice 61-62 Price Lists: 63- • Capsules & Tablets 64-69 • Injections 70-73 • Creams & Foams 74-75 • Troches & Gummies 76-77 • Nasal & Eye Drops 77 • IV + Protocols 78-79 3 Our Story Tailor Made Compounding was launched in the U.S. in January of 2016. We have since become a major contributor to peptide medicines in the integrative health space. Through our compounding expertise, knowledge and experience, we have quickly grown as one of the top compounding pharmacies in the nation. Together, with our sister pharmacies around the world, we have established a reputation for working closely with our physicians and are well known for obtaining difficult to source and hard to compound pharmaceuticals. Our sister facility and first establishment, Como compounding in Melbourne, has been working with peptide therapies for over a decade. After witnessing the success these products were having for both doctors and patients in Australia, we saw the demand to bring our compounding expertise to the United States. At Tailor Made, we pride ourselves in being partners with our practitioners and their staff. That’s why a major part of what we do involves educating our prescribers on the products we develop, including their clinical indications, and dosing. Through building these relationships and creating cutting-edge peptide therapies, we promise to maintain our status as leaders in the industry. Collectively, all of our locations work to support the same mission; To positively disrupt medicine using innovative technologies through education and partnership. 4 Positively disrupting medicine using innovative technology. 5 MARKETING SHEETS 6 ANTI-AGING PRODUCTS Dasatinib- Dasatinib is a targeted therapy, classified as a signal transduction inhibitor, used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasatinib binds to and inhibits the growth-promoting activities of SRC-family protein-tyrosine kinases, which interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways. Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence- associated secretory phenotype (SASP), accumulate with aging and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin, selectively eliminate senescent cells by transiently disabling pro-survival networks that defend them against their own apoptotic environment. In the first clinical trial of senolytics, Dasatinib + Quercetan improved physical function in patients with idiopathic pulmonary fibrosis (IPF), a fatal senescence-associated disease. Product: Dasatinib 50mg capsule Protocol: Take 2 capsules by mouth daily for 3 days Rapamycin (Sirolimus)- Rapamycin was initially discovered as an antifungal metabolite produced by Streptomyces hygroscopicus from a soil sample of Easter Island. This medication has been found to possess immunosuppressive and anti-proliferative properties in mammalian cells due to its ability to inhibit mTOR. Rapamycin is a potent inhibitor of antigen-induced proliferation of T cells, B cells, and antibody production. Interest in sirolimus as an immunosuppressive therapy in organ transplantation derives from its unique mechanism of action, its unique side-effect profile, and its ability to synergize with other immunosuppressive agents.Rapamycin’s immunosuppressive and anti-proliferative properties have led to its use in the prevention of organ transplant rejection. mTOR has been implicated in many of the processes that are associated with aging, including cellular senescence, immune responses, cell stem regulation, autophagy, mitochondrial function, and protein homeostasis (proteostasis). Furthermore, Product: Sirolimus 3mg capsule & Rapamycin’s inhibition of mTOR has been shown to regulate Sirolimus 0.001% cream in a 30mL cell senescence thus reducing it’s age-related pathology and Topi-CLICK® loss of function. This will ultimately improve physiological Protocol: Take 1 capsule by mouth once function and extend longevity. The downstream events that weekly. Apply a thin layer of cream follow the inactivation of TOR result in the blockage of topically to the face once daily. cell-cycle progression at the juncture of G1 and S phase. Tailor Made Compounding Pharmacy | Ph: 1 859 887 0013 | Fax: 1 859 406 1242 | [email protected] 7 GROWTH HORMONE PRODUCTS Growth hormone (GH) also known as human growth hormone (hGH) in its human form, is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans and other animals.GH stimulates production of IGF-1 and increases the concentration of glucose and free fatty acids.[1][2] GH is a 191-amino acid, single-chain polypeptide that is synthesized, stored and secreted by somatotropic cells within the lateral wings of the anterior pituitary gland. When growth hormone is released from the pituitary gland, it signals the liver to release a second hormone, called insulin-like growth factor-1 (IGF-1). Together, growth hormone and IGF-1 tell the bones, muscles, and other organs and tissues to grow by adding more cells Norditropin FlexPro Pen The FlexPro® pen is a delivery device that comes prefilled and preloaded. 5mg: $700.00 10mg: $1,300.00 15mg: $2,020.00 Did you know that GH can also help the immune system? In mammals, the thymus supports maturation of thymocytes into T-cells and to maintain immunological tolerance. This is an important part of what makes your immune system work. The thymus continually atrophies after childhood, it’s epithelia is replaced by adipose tissue, and it has been hypothesized that at least some immune dysfunction associated with aging is caused by the loss of thymus tissue. For example, infants whose thymus was removed during cardiac surgery at 18 years after surgery have immune cell populations more reminiscent of 65-70 year olds. Multiple factors have been tested preclinically to try and regenerate the Thymus. The thymic epithelia not only express GH receptors, but secrete GH in a positive feedback loop. By using growth hormone, you can regenerate the thymus and prevent immunosenescence! 8 Tailor Made Compounding Pharmacy | Ph: 1 859 887 0013 | Fax: 1 859 406 1242 | [email protected] GROWTH HORMONE PRODUCTS Omnitrope Ready-to-use liquid cartridge eliminates the need to reconstitute or mix with a liquid Injectable 5.8mg: $360.00 Saizen Saizen is a human growth hormone produced by recombinant DNA technology 5mg vial: $489.00 Zomacton Zomacton is a sterile, white, lyophilized powder, for subcutaneous use, after reconstitution with the 5mg: $348.00 accompanying diluent Tailor Made Compounding Pharmacy | Ph: 1 859 887 0013 | Fax: 1 859 406 1242 | [email protected] 9 HORMONE REPLACEMENT THERAPIES DHEA- DHEA is the most abundant hormone found in humans and is a precursor to many other steroids. DHEA declines steadily as we age, and low levels of DHEA have been associated with Alzheimer’s disease, cancer, and atherosclerotic disease. DHEA offers you an exciting option to help increase natural testosterone production. Pricing: Benefits of DHEA: 25mg capsule $0.53 Helps boost testosterone, aids in immune support, promotes 50mg capsule $0.63 weight loss, enhances libido, improves sports performance and 100mg capsule $0.70 muscle mass. DHEA is also thought to slow the aging process and Suggested dosage: Take 1 combat bone density loss in women. capsule by mouth once daily Thyroid- The thyroid gland secretes two hormones (triiodothyronine and thyroxine). These hormones are responsible for regulating basal metabolic rate, neurotransmitter production and release (e.g., dopamine, serotonin, norepinephrine), neural development, and it protects against arrhythmias (abnormal heartbeat). Many patients with clinical or subclinical hypothyroidism may experience symptoms such as fatigue/lethargy, depression, memory loss, anxiety, constipation, dry skin and hair, cold sensitivity, insomnia, and unexplained weight gain or inability to lose weight. Given these factors, a combination of both T3 and T4 is often essential for thyroid optimization. Custom liothyronine and levothyroxine compounded formulations are available in addition to the commercial options. Benefits of Thyroid: Improves energy, aids in weight loss, better tolerance to temperature changes, better sleep, improved skin tone, decrease water retention, normalized bowel
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Aromasin (Exemestane)
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ADVERSE REACTIONS------------------------------­ These highlights do not include all the information needed to use • Early breast cancer: Adverse reactions occurring in ≥10% of patients in AROMASIN safely and effectively. See full prescribing information for any treatment group (AROMASIN vs. tamoxifen) were hot flushes AROMASIN. (21.2% vs. 19.9%), fatigue (16.1% vs. 14.7%), arthralgia (14.6% vs. 8.6%), headache (13.1% vs. 10.8%), insomnia (12.4% vs. 8.9%), and AROMASIN® (exemestane) tablets, for oral use increased sweating (11.8% vs. 10.4%). Discontinuation rates due to AEs Initial U.S. Approval: 1999 were similar between AROMASIN and tamoxifen (6.3% vs. 5.1%). Incidences of cardiac ischemic events (myocardial infarction, angina, ----------------------------INDICATIONS AND USAGE--------------------------- and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%. AROMASIN is an aromatase inhibitor indicated for: Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6, • adjuvant treatment of postmenopausal women with estrogen-receptor 6.1). positive early breast cancer who have received two to three years of • Advanced breast cancer: Most common adverse reactions were mild to tamoxifen and are switched to AROMASIN for completion of a total of moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%), five consecutive years of adjuvant hormonal therapy (14.1). fatigue (8% vs. 10%), increased sweating (4% vs. 8%), and increased • treatment of advanced breast cancer in postmenopausal women whose appetite (3% vs. 6%) for AROMASIN and megestrol acetate, disease has progressed following tamoxifen therapy (14.2). respectively (6, 6.1). ----------------------DOSAGE AND ADMINISTRATION----------------------- To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at Recommended Dose: One 25 mg tablet once daily after a meal (2.1).
    [Show full text]
  • First Reversals of Cognitive Decline in Alzheimer's Disease and Its
    1/12/2017 First Reversals of Cognitive Decline in Alzheimer’sSystems Therapeutics, Disease and its PresidentPrecursors, Obama, MCI and and the End ofSCI Alzheimer’s Disease Dale E. Bredesen, M.D. Augustus Rose Professor Easton Laboratories for Neurodegenerative Disease Research UCLA Founding President, Buck Institute “There is nothing that will prevent, reverse, or slow the progress of Alzheimer’s disease.” “Everyone knows someone who is a cancer survivor; no one knows an Alzheimer’s survivor.” 1 1/12/2017 30,000,000 patients in 2012 3rd leading cause (James, B. D. et al. Contribution of Alzheimer disease to mortality in the United States. Neurology 82, 1045-1050, doi:10.1212/WNL. 0240 (2014) Pres. Obama and NAPA, 2011 160,000,000 patients in 2050 2 1/12/2017 Women at the epicenter of the epidemic •65% of patients •60% of caregivers •More common than breast cancer 0 Cures 3 1/12/2017 Alzheimer’s Disease (AD) Therapeutic Landscape A production APPROVED A aggregation Donepezil (Aricept) A clearance Rivastigmine (Exelon) Tau aggregation/phosph Galantamine (Razadyne) Cholinergic drugs Tacrine (Cognex) Others Memantine (Namenda) PHASE 3 PHASE 2 PHASE 1 Solanezumab ELND005 PBT2 AL-108 GSK933776 NIC5-15 PF04360365 AF102B MABT5102A Bapineuzmab Valproate Bryostatin-1 Nicotinamide Talsaclidine EHT-0202 NP12 ACC001 UB311 Alzemed Antioxidant BMS708163 Lithium AN1792 R1450 Begacestat Semagacestat Statins ABT089 NGF CAD106 V950 PF3084014 AZD3480 SB742457 Flurizan Dimebon E2012 Huperzine-A PRX03140 CTS21166 Rosiglitazone EGCg EVP6124 PUFA MK0752 MEM3454 TTP448 Phenserine CHF5074 PF-04447943 Clinical Trial in AD terminated “Game of Throwns” (243/244) R.I.P. R.I.P. R.I.P.
    [Show full text]
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • Mode of Action
    STROKE TBI DEMENTIA Mode of Action Reconnecting Neurons. Empowering for Life. NEW MULTI-MODAL THERAPIES FOR NEUROLOGICAL DISORDERS Sonic hedgehog (Shh) The Sonic Hedgehog (Shh) signalling pathway regulates the development Smoothened of organs including the organization of the brain. For example, the Shh (Smo) Patched (Ptch) activates the Gli complex, which is responsible for the expression of develop- mental genes underpinning neurorecovery and leading to an amplification of natural recovery. Gli Complex Gli Repressor Gli Activator Cerebrolysin activates the Shh pathway1 Cerebrolysin has a promoting effect on neurogenesis and oligodendrogenesis via stimulating the expression of the Shh signalling pathway. Cerebrolysin increases mRNA modulation of Shh and its receptors ‘Patched’ (Ptch) and ‘Smoothened’ (Smo). Shh PTCH Smo 5 * * 3 * 3 4 (n=9) (n=9) *p<0.05 (n=9) *p<0.05 *p<0.05 3 2 2 2 1 1 Fold changes (mean±SE) changes Fold (mean±SE) changes Fold 1 (mean±SE) changes Fold 0 0 0 0 20 0 20 0 20 CERE (µl/ml) CERE (µl/ml) CERE (µl/ml) Figure 1: Cerebrolysin stimulates the expression of the sonic hedgehog signalling pathway components in neural progenitor cells. Graphs show mRNA levels in an in vitro experiment. Studies confirm the important role of the sonic hedgehog pathway in post-stroke brain repair and functional recovery, and suggests the Shh pathway to be a possible target for prolongation of the therapeutic window after stroke.2 MAINTENANCE AND RECOVERY OF THE NEURONAL NETWORK Neurotrophic factors (NTFs) are signaling molecules that maintain, protect, and restore the neuronal network and ensure proper functioning of the brain.
    [Show full text]
  • Randomized Controlled Pilot Trial of Cabergoline, Hydergine and Levodopa/Carbidopa: Los Angeles Cocaine Rapid Efficacy Screening
    Blackwell Science, LtdOxford, UKADDAddiction1359-6357© 2005 Society for the Study of Addiction 100•••• Original Article Cabergoline, hydergine, levodopa/carbidopa Steven Shoptaw et al. RESEARCH REPORT Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST) Steven Shoptaw1, Donnie W. Watson2, Chris Reiber1, Richard A. Rawson1, Margaret A. Montgomery3, Maria D. Majewska3 & Walter Ling1 UCLA Integrated Substance Abuse Programs, Los Angeles, CA1 , Friends Research Institute, Inc., Los Angeles, CA2 and National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA3 Correspondence to: ABSTRACT Steven Shoptaw PhD UCLA/Integrated Substance Abuse Programs Aim This study tested three dopaminergic medications against a common 11075 Santa Monica Blvd unmatched placebo condition: hydergine 1 mg three times daily (n = 15); Suite 200 levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg Los Angeles per week (n = 15); and placebo three times daily (n = 15) as potential pharma- CA 90025 USA cotherapies for cocaine dependence. E-mail: [email protected] Design The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive RESEARCH REPORT behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination. Measures Outcomes included cocaine metabolites measured in urine, reten- tion and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors. Results Participants assigned to receive cabergoline provided more urine sam- ples negative for cocaine metabolites (42.4%) than those assigned to receive pla- cebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05).
    [Show full text]
  • Workbook Psychiatry and Narcology
    Kharkiv National Medical University Department of Psychiatry, Narcology and Medical Psychology WORKBOOK MANUAL FOR INDIVIDUAL WORK FOR MEDICAL STUDENTS PSYCHIATRY AND NARCOLOGY (Part 2) Student ___________________________________________________________ Faculty _________________________________________________________ Course _________________ Group _____________________________________ Kharkiv 2019 Затверджено вченою радою ХНМУ Протокол №5 від 23.05.2019 р. Psychiatry (Part 2) : workbook manual for individual work of students / I. Strelnikova, G. Samardacova, К. Zelenska – Kharkiv, 2019. – 103 p. Копіювання для розповсюдження в будь-якому вигляді частин або повністю можливо тільки з дозволу авторів навчального посібника. CLASS 7. NEUROTIC DISORDERS. CLINICAL FORMS. TREATMENT AND REHABILITATION. POSTTRAUMATIC STRESS DISORDER. TREATMENT AND REHABILITATION. Psychogenic diseases are a large and clinically varied group of diseases resulting from an effect of acute or long-term psychic traumas, which manifest themselves by both mental and somatoneurological disorders and, as a rule, are reversible. Psychogenic diseases are caused by a psychic trauma, i.e. some events which affect significant aspects of existence of the human being and result in deep psychological feelings. These may be subjectively significant events, i.e. those which are pathogenic for the majority of people. Besides, the psyche may be traumatized by conventionally pathogenic events, which cause feelings in an individual because of his peculiar hierarchy of values. Unfavorable psychogenic effects on the human being cause stress in him, i.e. a nonspecific reaction at the physiological, psychological and behavioural levels. Stress may exert some positive, mobilizing influence, but may result in disorganization of the organism activity. The stress, which exerts a negative influence and causes various disturbances and even diseases, is termed distress. Classification of neurotic disorders I.
    [Show full text]
  • Prot SAP 000.Pdf
    UW17032 Version 10/03/2019 Alterations in the vaginal microenvironment using a non-pharmacological intervention for breast cancer patients treated with aromatase inhibitors PRINCIPAL INVESTIGATOR: Ryan J. Spencer, MD, MS Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Wisconsin School of Medicine and Public Health Co-Investigators: Amye Tevaarwerk, MD Department of Medicine Division of Hematology/Oncology University of Wisconsin School of Medicine and Public Health Lori Seaborne, PA-C UWCCC Breast Center Department of Surgery University of Wisconsin Carbone Cancer Center Josephine Harter, MD Department of Pathology University of Wisconsin School of Medicine and Public Health Biostatistics: Colin Longhurst, MS Department of Biostatistics and Medical Informatics University of Wisconsin School of Medicine and Public Health Page 1 of 22 UW17032 Version 10/03/2019 Table of Contents Study Schema & Proposed Timeline Diagrams ........................................................................................... 3 1.0 Introduction ...................................................................................................................................................... 3 2.0 Study Hypothesis and Objectives .............................................................................................................. 4 3.0 Study Design Overview & Rationale ......................................................................................................... 4 4.0 Recruitment and Enrollment
    [Show full text]
  • The Ndac (Neurology and Psychiatry) Held on 17.12.2011
    1. RECOMMENDATIONS OF THE NDAC (NEUROLOGY AND PSYCHIATRY) HELD ON 17.12.2011:- The NDAC (Neurology and Psychiatry) deliberated the proposals on 17.12.2011and recommended the following:- AGENDA DRUG NAME RECOMMENDATIONS NO. Global Clinical Trials The drug has not yet been studied / approved in the country in adults. The tools to assess the cognitive affects are also not included in the 1 Rufinamide protocol except CBCL (child behaviours check list) which is not adequate. In view of above, the proposal to conduct the study in children 1 to 4 years of age was not recommended. DEFFREED Recommended for granting permission for the conduct of proposed study subject to following conditions: That subject from extension study 01050256 2 Lurasidone HCl should only be rolled over to the proposed study. Patients aged 18 to 65 years only should be included in the study. Since the study involves use of placebo without rescue medication in one arm in patients with 3 OPC-34712 acute schizophrenia, the proposal was not recommended for grant of permission. Since the study involves use of placebo without rescue medication in one arm in patients with 4 OPC-34712 acute schizophrenia, the proposal was not recommended for grant of permission. Recommended for granting permission for the 5 BMS-820836 conduct of proposed study. Patients aged 18 to 65 years only should be included in the study. Recommended for granting permission for the 6 BMS-820836 conduct of proposed study. Patients aged 18 to 65 years only should be included in the study. There were earlier studies conducted in USA which had failed as there was no statistically significant effect of the study drug at dose level of 5, 10 mg per day over placebo.
    [Show full text]
  • Vaginal Atrophy After Breast Cancer
    Information Sheet Vaginal atrophy after breast cancer Women who have had breast cancer treatment but not yet gone through the menopause might find they develop symptoms such as hot flushes, night sweats and vaginal dryness. These are symptoms of oestrogen deficiency, which occur naturally with age, but may also occur in younger women undergoing treatment for breast cancer. Unlike some menopausal symptoms, such as hot flushes, which may go away as time passes, vaginal atrophy often persists and may get worse with time. Today’s increased use of adjuvant treatments (medications that are used after surgery/chemotherapy/radiotherapy) --which evidence shows reduce the risk of the cancer recurring-- unfortunately lead to more side-effects. Your health and comfort is important, so don’t be embarrassed about raising these issues with your doctor. This leaflet offers some advice for what you can do to maintain the health of your vagina, your vulva (the external genitals) and your urethra (outlet from the bladder), with special attention to the needs of women who have had breast cancer treatment. Why is oestrogen important for vaginal health? The vaginal area needs adequate levels of oestrogen to maintain healthy tissue. The vagina’s epithelium, or lining, contains oestrogen receptors which, when stimulated by the hormone, keep the walls thick and elastic. When circulating oestrogen decreases, the vaginal lining becomes thinner and drier. A healthy vagina is naturally acidic, but with menopause it may develop a higher pH (become more alkaline) which leaves women more susceptible to urinary tract infections. The vulval area also changes with ageing, as fatty tissue reduces and the labia majora (outer lips of the vagina) and the hood of skin covering the clitoris may contract.
    [Show full text]
  • Cphi & P-MEC China Exhibition List展商名单version版本20180116
    CPhI & P-MEC China Exhibition List展商名单 Version版本 20180116 Booth/ Company Name/公司中英文名 Product/产品 展位号 Carbosynth Ltd E1A01 Toronto Research Chemicals Inc E1A08 SiliCycle Inc. E1A10 SA TOURNAIRE E1A11 Indena SpA E1A17 Trifarma E1A21 LLC Velpharma E1A25 Anuh Pharma E1A31 Chemclone Industries E1A51 Hetero Labs Limited E1B09 Concord Biotech Limited E1B10 ScinoPharm Taiwan Ltd E1B11 Dongkook Pharmaceutical Co., Ltd. E1B19 Shenzhen Salubris Pharmaceuticals Co., Ltd E1B22 GfM mbH E1B25 Leawell International Ltd E1B28 DCS Pharma AG E1B31 Agno Pharma E1B32 Newchem Spa E1B35 APEX HEALTHCARE LIMITED E1B51 AMRI E1C21 Aarti Drugs Limited E1C25 Espee Group Innovators E1C31 Ruland Chemical Co., Ltd. E1C32 Merck Chemicals (Shanghai) Co., Ltd. E1C51 Mediking Pharmaceutical Group Ltd E1C57 珠海联邦制药股份有限公司/The United E1D01 Laboratories International Holdings Ltd. FMC Corporation E1D02 Kingchem (Liaoning) Chemical Co., Ltd E1D10 Doosan Corporation E1D22 Sunasia Co., Ltd. E1D25 Bolon Pharmachem Co., Ltd. E1D26 Savior Lifetec Corporation E1D27 Alchem International Pvt Ltd E1D31 Polish Investment and Trade Agency E1D57 Fischer Chemicals AG E1E01 NGL Fine Chem Limited E1E24 常州艾柯轧辊有限公司/ECCO Roller E1E25 Linnea SA E1E26 Everlight Chemical Industrial Corporation E1E27 HARMAN FINOCHEM E1E28 Zhechem Co Ltd E1F01 Midas Pharma GmbH Shanghai Representativ E1F03 Supriya Lifescience Ltd E1F10 KOA Shoji Co Ltd E1F22 NOF Corporation E1F24 上海贺利氏工业技术材料有限公司/Heraeus E1F26 Materials Technology Shanghai Ltd. Novacyl Asia Pacific Ltd E1F28 PharmSol Europe Limited E1F32 Bachem AG E1F35 Louston International Inc. E1F51 High Science Co Ltd E1F55 Chemsphere Technology Inc. E1F57a PharmaCore Biotech Co., Ltd. E1F57b Rockwood Lithium GmbH E1G51 Sarv Bio Labs Pvt Ltd E1G57 抗病毒类、抗肿瘤类、抗感染类和甾体类中间体、原料药和药物制剂及医药合约研发和加工服务 上海创诺医药集团有限公司/Shanghai Desano APIs and Finished products of ARV, Oncology, Anti-infection and Hormone drugs and E1H01 Pharmaceuticals Co., Ltd.
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]